Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: UHAC 62 XX capsule
Drug: UHAC 62 XX tablet

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 26

Registration Number: NCT02187575

BIBR 277 Capsules in Hypertensive Patients With Nephropathy

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: BIBR 277

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT02187484

Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Aspirin
Drug: Meloxicam

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02187562

Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine

Phase 1

Completed

Conditions: Renal Insufficiency
Hepatic Insufficiency

Interventions: Drug: Nevirapine

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT02184091

Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients

Phase 1

Terminated

Conditions: HIV Infections

Interventions: Drug: Nevirapine
Drug: Saquinavir-sgc

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT02184286

Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Meloxicam

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22639

Registration Number: NCT02184065

Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nevirapine XR low dose
Drug: Nevirapine XR medium dose
Drug: Nevirapine XR high dose
Drug: Nevirapine (VIRAMUNE®)

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02184312

Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke

Phase 4

Terminated

Conditions: Stroke

Interventions: Drug: Metamizole
Drug: Placebo

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT02184260

Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases

Completed

Conditions: Osteoarthritis

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12687

Registration Number: NCT02184039

Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children

Phase 2

Completed

Conditions: Healthy

Interventions: Drug: Kiddi® Pharmaton Fizz, effervescent tablets
Drug: Comparator product

First Posted Date: 2014-07-09

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 96

Registration Number: NCT02184325

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy